Clinical Trial Update: XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients. [NA]

View source ↗

Summary

A completed clinical trial evaluating the safety of 3-month dual antiplatelet therapy after XIENCE implantation in high-bleeding-risk patients; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Artery Lesions

Drugs mentioned

• Xience (everolimus-eluting stent with permanent polymer)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Artery Lesions | NA | Status: COMPLETED | Results posted: 2021-11-05